Clinical Trial Update: Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) [Phase 2]

View source ↗

Summary

Phase 2 trial of lonafarnib in patients with recurrent squamous cell carcinoma of the head and neck has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Lonafarnib (lonafarnib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Squamous Cell, Head and Neck Neoplasms | Phase 2 | Status: TERMINATED